Humana Inc. (NYSE:HUM) Shares Acquired by Pekin Hardy Strauss Inc.

Pekin Hardy Strauss Inc. grew its holdings in Humana Inc. (NYSE:HUM) by 5.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 33,584 shares of the insurance provider’s stock after buying an additional 1,735 shares during the period. Humana accounts for about 1.1% of Pekin Hardy Strauss Inc.’s holdings, making the stock its 16th biggest holding. Pekin Hardy Strauss Inc.’s holdings in Humana were worth $8,521,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of HUM. AMF Tjanstepension AB grew its holdings in shares of Humana by 166.8% in the third quarter. AMF Tjanstepension AB now owns 40,051 shares of the insurance provider’s stock valued at $12,686,000 after purchasing an additional 25,041 shares during the period. Sequoia Financial Advisors LLC grew its holdings in shares of Humana by 3.2% in the third quarter. Sequoia Financial Advisors LLC now owns 2,408 shares of the insurance provider’s stock valued at $763,000 after purchasing an additional 74 shares during the period. Eastern Bank purchased a new stake in shares of Humana in the third quarter valued at about $90,000. IFM Investors Pty Ltd grew its holdings in shares of Humana by 0.5% in the third quarter. IFM Investors Pty Ltd now owns 25,370 shares of the insurance provider’s stock valued at $8,036,000 after purchasing an additional 131 shares during the period. Finally, Assenagon Asset Management S.A. grew its holdings in shares of Humana by 12.7% in the third quarter. Assenagon Asset Management S.A. now owns 4,090 shares of the insurance provider’s stock valued at $1,295,000 after purchasing an additional 461 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Stock Down 5.7 %

Shares of NYSE:HUM opened at $255.77 on Friday. The firm’s 50 day moving average price is $269.41 and its 200 day moving average price is $290.00. The stock has a market cap of $30.80 billion, a price-to-earnings ratio of 25.71, a price-to-earnings-growth ratio of 2.05 and a beta of 0.56. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last issued its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, equities research analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a yield of 1.38%. Humana’s payout ratio is currently 35.58%.

Insiders Place Their Bets

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.32% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

HUM has been the subject of a number of analyst reports. Truist Financial upped their price objective on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a report on Monday, January 6th. Morgan Stanley lowered their target price on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 12th. Barclays increased their target price on shares of Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. Bank of America raised shares of Humana from an “underperform” rating to a “neutral” rating and increased their target price for the stock from $247.00 to $308.00 in a research note on Wednesday, November 6th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $290.00 target price on shares of Humana in a research note on Wednesday, February 12th. Nineteen research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.